Stryker Corporation (NYSE: SYK) is one of the most important medical technology companies in the world, spanning orthopedics, surgical equipment, neurotechnology, and hospital systems. Shares recently traded around $364, valuing the company at approximately $139.2 billion based on 382.42 million shares outstanding.
Founded by Dr. Homer Stryker, the business has evolved into a durable compounder powered by recurring revenue, consistent procedure demand, and strong returns on capital. Understanding who owns Stryker today, along with recent hedge fund moves and insider trades, helps reveal how the most informed investors are positioning around the company.
Who Are Stryker’s Top Shareholders?
Stryker’s shareholder base is anchored by major passive institutions like Vanguard, BlackRock, and State Street. These firms typically hold through market cycles, providing long term stability. Active managers made a mix of additions and reductions that reflect a selective but steady outlook on the company.
Stryker’s Largest Shareholders
- The Vanguard Group: 33,615,131 shares (8.79%), $12.24B value. Added 267,302 shares (+0.80%).
- Brown (John W): 20,056,245 shares (5.24%), $7.30B value. No change reported.
- Greenleaf Trust: 16,643,488 shares (4.35%), $6.06B value. Cut 45,736 shares (0.27%).
- BlackRock Institutional Trust: 16,264,210 shares (4.25%), $5.92B value. Added 181,927 shares (+1.13%).
- State Street Investment Management: 14,942,900 shares (3.91%), $5.44B value. Cut 13,832 shares (0.09%).
- T. Rowe Price Associates: 10,478,078 shares (2.74%), $3.81B value. Cut 908,393 shares (7.98%).
- Geode Capital: 7,465,721 shares (1.95%), $2.72B value. Added 72,110 shares (+0.98%).
- J.P. Morgan Asset Management: 7,136,721 shares (1.87%), $2.60B value. Cut 232,173 shares (3.15%).
- AllianceBernstein: 6,338,050 shares (1.66%), $2.31B value. Added 741,542 shares (+13.25%).
- Capital Research Global Investors: 6,274,304 shares (1.64%), $2.28B value. Cut 492,303 shares (7.28%).
- Wellington Management: 5,294,611 shares (1.38%), $1.93B value. Cut 265,078 shares (4.77%).
- Fidelity Management & Research: 4,773,612 shares (1.25%), $1.74B value. Cut 1,903,443 shares (28.51%).
With several active managers trimming and others increasing exposure, this mix suggests investors still view Stryker as a high quality compounder with reliable margins and consistent earnings, while staying mindful of valuation at current price levels.
Hedge Fund Highlights
One highlight from last quarter is Squarepoint Ops’ massive move, lifting its Stryker position by 3,842% and now holding roughly $287 million worth of the stock. This appears to show a more positive stance toward Stryker’s steady procedure volume and strong margin profile.
Another notable shift comes from Jane Street Group, which boosted its stake by 23,291% to about $86 million, a jump that may reflect rising trading activity around Stryker’s liquidity, index flows, and consistent fundamentals.
Rounding out the quarter’s largest moves is GAMCO Investors, led by Mario Gabelli, which increased its holdings by 35.88% to roughly $6.22 million, suggesting growing confidence in Stryker’s cash flow durability and long term compounding potential.
Together these shifts indicate that hedge funds, despite having different strategies, are showing stronger interest in Stryker’s stability and dependable performance.
Track the top shareholders of over 50,000 global stocks (It’s free) >>>
Stryker’s Recent Insider Trades
Insider trades can offer a useful view into how confident executives and directors may be feeling about the stock. Recent filings show several sales from long time holders and a few small administrative entries.
Recent Insider Activity
- Ronda Stryker (Director): Sold 396 to 141,052 shares across multiple trades on 11/5/25 at prices ranging from $349.95 to $355.80.
- William E. Berry Jr (Officer): Sold 1,953 shares at $365.49 and 2,972 shares at $373.42, while also adding 4,925 shares at $154.14, which may relate to vesting or an award settlement.
- Preston Wendell Wells (Officer): Sold 165 shares at $365.88.
- James Andrew Pierce (Officer): Multiple small entries around 100 shares that may be tied to administrative adjustments or compensation timing.
- Other entries: Include small movements of 1 to 2 shares by directors or officers that appear administrative rather than meaningful buys.
These trades do not materially shift overall insider ownership, but they help show how leadership may be managing personal exposure at current price levels.
See recent insider trade data for over 50,000 global stocks (It’s free) >>>
What the Ownership & Insider Trade Data Tell Us
Stryker continues to be supported by a strong institutional base, with passive giants providing long term stability and active managers adjusting selectively. Hedge fund interest rose sharply this quarter, while insider selling looks more like personal portfolio management than a directional signal.
Altogether this ownership picture reinforces Stryker’s positioning as a high quality medical technology compounder with durable margins, recurring revenue, and steady demand across healthcare systems.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
